The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Sign Up to like & getrecommendations! Published in 2022 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2022.121518
Abstract: Despite the remarkable success of immunotherapies over the past decade, their effectiveness against triple-negative breast cancer (TNBC) is limited to a small subset of patients, mainly due to the low immunogenicity and unfavorable tumor microenvironment.… read more here.
Keywords: programmed site; microenvironment; specific delivery; site specific ... See more keywords